CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


UlinastatinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug189 Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D053717 Pneumonia, Ventilator-Associated NIH 0.33
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

The primary objective of this study is to evaluate the safety and efficacy of intravenous (IV) infusion of ulinastatin compared to placebo with respect to time to recovery, disease severity, need for ventilator support, and mortality in patients with COVID 19.

NCT04393311 COVID-19 Drug: Ulinastatin Drug: Placebo

Primary Outcomes

Description: Time to recovery, defined as attaining a score of 6, 7, or 8 on the COVID-19 disease severity scale, an 8 point ordinal scale used in the NIH Adaptive COVID-19 Treatment Trial (ACTT; NCT04280705). = Death; = Hospitalized and on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); = Hospitalized and on non-invasive ventilation or high-flow oxygen devices; = Hospitalized and requiring supplemental oxygen; = Hospitalized and not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or otherwise); = Hospitalized and not requiring supplemental oxygen and no longer requiring ongoing medical care; = Not hospitalized, limitation on activities and/or requiring home oxygen; = Not hospitalized, no limitation on activities

Measure: Time to recovery

Time: Up to 29 days

Secondary Outcomes

Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).

Measure: COVID-19 disease severity scale score on Day 8

Time: Day 8

Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).

Measure: COVID-19 disease severity scale score on Day 15

Time: Day 15

Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).

Measure: COVID-19 disease severity scale score on Day 22

Time: Day 22

Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).

Measure: COVID-19 disease severity scale score on Day 29

Time: Day 29

Measure: Incidence of mortality at Day 29

Time: 29 days

Measure: Incidence of in-hospital mortality

Time: Up to 29 days

Measure: Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose

Time: Up to 29 days

Measure: Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29

Time: Day 29

Measure: Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29

Time: Day 29

Description: For patients requiring mechanical ventilation.

Measure: Duration of mechanical ventilation

Time: Up to 29 days

Description: For patients requiring mechanical ECMO.

Measure: Duration of ECMO

Time: Up to 29 days

Description: For patients requiring non-invasive ventilation

Measure: Duration of noninvasive ventilation

Time: Up to 29 days

Description: For patients admitted to ICU

Measure: Duration of ICU stay

Time: Up to 29 days

Measure: Duration of hospital stay

Time: Up to 29 days

Measure: Change in oxygen saturation

Time: Between screening and 24 hours after last dose (up to 11 days)


No related HPO nodes (Using clinical trials)